Cytogen Inc Asset Resilience Ratio
Cytogen Inc asset resilience ratio. Cytogen Inc (217330) has an Asset Resilience Ratio of 32.97% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Cytogen Inc (217330) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Cytogen Inc (2016–2025)
Asset resilience ratio of Cytogen Inc from 2016 to 2025. This chart shows how Cytogen Inc's Asset Resilience Ratio has changed over time. Read 217330 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Cytogen Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Cytogen Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩20.52 Billion | 32.97% |
| Total Liquid Assets | ₩20.52 Billion | 32.97% |
Asset Resilience Insights
- Very High Liquidity: Cytogen Inc maintains exceptional liquid asset reserves at 32.97% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cytogen Inc Industry Peers by Asset Resilience Ratio
Compare Cytogen Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revvity Inc.
NYSE:RVTY |
Diagnostics & Research | 0.00% |
|
Diagnósticos da América S.A
SA:DASA3 |
Diagnostics & Research | 10.42% |
|
SMO ClinPlus Co. Ltd.
SHE:301257 |
Diagnostics & Research | 15.78% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
Cytogen Inc Asset Resilience Ratio by Year (2016–2025)
Cytogen Inc asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Cytogen Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 32.97% | ₩20.52 Billion ≈ $13.91 Million |
₩62.24 Billion ≈ $42.18 Million |
-23.87pp |
| 2024-12-31 | 56.85% | ₩41.20 Billion ≈ $27.92 Million |
₩72.48 Billion ≈ $49.12 Million |
-16.88pp |
| 2023-12-31 | 73.72% | ₩54.89 Billion ≈ $37.20 Million |
₩74.45 Billion ≈ $50.45 Million |
+34.66pp |
| 2022-12-31 | 39.06% | ₩16.10 Billion ≈ $10.91 Million |
₩41.22 Billion ≈ $27.93 Million |
-24.65pp |
| 2021-12-31 | 63.71% | ₩35.38 Billion ≈ $23.97 Million |
₩55.53 Billion ≈ $37.63 Million |
+7.57pp |
| 2020-12-31 | 56.14% | ₩15.89 Billion ≈ $10.77 Million |
₩28.31 Billion ≈ $19.19 Million |
-8.89pp |
| 2019-12-31 | 65.03% | ₩12.82 Billion ≈ $8.69 Million |
₩19.72 Billion ≈ $13.36 Million |
+9.11pp |
| 2018-12-31 | 55.92% | ₩12.72 Billion ≈ $8.62 Million |
₩22.75 Billion ≈ $15.42 Million |
-23.46pp |
| 2017-12-31 | 79.38% | ₩4.51 Billion ≈ $3.06 Million |
₩5.68 Billion ≈ $3.85 Million |
+24.16pp |
| 2016-12-31 | 55.22% | ₩2.80 Billion ≈ $1.89 Million |
₩5.06 Billion ≈ $3.43 Million |
-- |
About Cytogen Inc
Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained wit… Read more